Allena Pharmaceuticals, Inc.
Recombinant uricase enzyme
Last updated:
Abstract:
Disclosed are recombinant mutant Candida utilis uricase enzymes with improved pancreatin stability and/or activity, compositions containing such uricase enzymes, which can be used, among other things, to treat diseases or disorders associated with an elevated amount of uric acid, including, for example, hyperuricemia, hyperuricosuria, and gout.
Status:
Grant
Type:
Utility
Filling date:
5 Nov 2019
Issue date:
27 Oct 2020